US Stock MarketDetailed Quotes
KPTI Karyopharm Therapeutics
- 0.845
- +0.067+8.67%
Close Nov 22 16:00 ET
- 0.835
- -0.010-1.17%
Post 19:24 ET
105.89MMarket Cap-804P/E (TTM)
0.868High0.770Low518.40KVolume0.770Open0.778Pre Close434.48KTurnover0.46%Turnover RatioLossP/E (Static)125.31MShares1.95052wk High-0.66P/B96.25MFloat Cap0.61752wk Low--Dividend TTM113.91MShs Float49.005Historical High--Div YieldTTM12.63%Amplitude0.617Historical Low0.838Avg Price1Lot Size
Karyopharm Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 7.70%38.78M | 13.86%42.79M | -14.40%33.13M | -7.03%146.03M | 0.50%33.75M | -0.38%36.01M | -5.29%37.58M | -18.82%38.7M | -25.14%157.07M | -73.41%33.58M |
| Operating revenue | 7.70%38.78M | 13.86%42.79M | -14.40%33.13M | -7.03%146.03M | 0.50%33.75M | -0.38%36.01M | -5.29%37.58M | -18.82%38.7M | -25.14%157.07M | -73.41%33.58M |
| Cost of revenue | 42.70%1.3M | 22.70%1.47M | 41.45%1.91M | -5.20%4.94M | -20.45%1.49M | -7.04%911K | 27.16%1.19M | -5.26%1.35M | 53.23%5.21M | 151.75%1.87M |
| Gross profit | 6.80%37.48M | 13.57%41.32M | -16.42%31.22M | -7.09%141.09M | 1.73%32.26M | -0.19%35.1M | -6.08%36.39M | -19.24%37.35M | -26.43%151.86M | -74.74%31.71M |
| Operating expense | -3.91%63.77M | 5.28%69.44M | -4.79%64.97M | -7.97%270.63M | 6.84%70.07M | 0.54%66.36M | -19.22%65.96M | -15.57%68.25M | -3.49%294.06M | -16.53%65.58M |
| Selling and administrative expenses | -10.30%27.63M | -9.89%31.07M | -17.71%29.55M | -9.30%131.88M | -11.43%30.69M | -11.08%30.81M | -7.65%34.48M | -7.38%35.91M | 1.08%145.4M | 0.25%34.65M |
| -General and administrative expense | -10.30%27.63M | -9.89%31.07M | -17.71%29.55M | -9.30%131.88M | -11.43%30.69M | -11.08%30.81M | -7.65%34.48M | -7.38%35.91M | 1.08%145.4M | 0.25%34.65M |
| Research and development costs | 1.63%36.13M | 21.90%38.37M | 9.54%35.43M | -6.67%138.75M | 27.31%39.38M | 13.37%35.55M | -28.96%31.48M | -23.12%32.34M | -7.57%148.66M | -29.70%30.93M |
| Operating profit | 15.92%-26.28M | 4.91%-28.12M | -9.26%-33.76M | 8.90%-129.54M | -11.63%-37.81M | -1.37%-31.26M | 31.08%-29.57M | 10.66%-30.9M | -44.70%-142.2M | -172.12%-33.87M |
| Net non-operating interest income expense | -187.48%-9.55M | -137.13%-7.02M | -28.15%-3.73M | 43.10%-12.88M | 18.96%-3.69M | 39.09%-3.32M | 50.83%-2.96M | 55.99%-2.91M | 11.10%-22.64M | 42.28%-4.55M |
| Non-operating interest income | -33.38%1.83M | -31.66%1.93M | -24.32%2.16M | 363.88%10.94M | 88.91%2.52M | 317.93%2.75M | 863.82%2.82M | 3,750.00%2.85M | 305.33%2.36M | 2,325.45%1.33M |
| Non-operating interest expense | 87.47%11.39M | 54.72%8.95M | 2.19%5.88M | -4.69%23.82M | 5.49%6.21M | -0.67%6.07M | -8.38%5.78M | -13.85%5.76M | -4.03%25M | -25.88%5.89M |
| Other net income (expense) | 4,160.67%3.79M | 196,560.00%59M | 174.24%196K | -328.92%-356K | -1,523.08%-211K | 456.25%89K | 330.77%30K | -261.64%-264K | 2.35%-83K | 97.28%-13K |
| Special income (charges) | --0 | --44.7M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| -Less:Other special charges | ---- | ---44.7M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | 4,160.67%3.79M | 47,553.33%14.3M | 174.24%196K | -328.92%-356K | -1,523.08%-211K | 456.25%89K | 330.77%30K | ---264K | 2.35%-83K | 97.28%-13K |
| Income before tax | 7.10%-32.04M | 173.41%23.86M | -9.45%-37.29M | 13.43%-142.78M | -8.52%-41.71M | 4.92%-34.49M | 33.59%-32.5M | 17.44%-34.07M | -33.19%-164.92M | -199.57%-38.43M |
| Income tax | 133.33%28K | -47.24%67K | 31.48%71K | -12.47%323K | 78.08%130K | -73.33%12K | 4.96%127K | -58.46%54K | 37.69%369K | 160.33%73K |
| Net income | 7.05%-32.07M | 172.91%23.79M | -9.48%-37.36M | 13.43%-143.1M | -8.65%-41.84M | 5.00%-34.51M | 33.49%-32.63M | 17.57%-34.13M | -33.20%-165.29M | -199.45%-38.51M |
| Net income continuous Operations | 7.05%-32.07M | 172.91%23.79M | -9.48%-37.36M | 13.43%-143.1M | -8.65%-41.84M | 5.00%-34.51M | 33.49%-32.63M | 17.57%-34.13M | -33.20%-165.29M | -199.45%-38.51M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 7.05%-32.07M | 172.91%23.79M | -9.48%-37.36M | 13.43%-143.1M | -8.65%-41.84M | 5.00%-34.51M | 33.49%-32.63M | 17.57%-34.13M | -33.20%-165.29M | -199.45%-38.51M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 5.54M | |||||||||
| Net income attributable to common stockholders | 7.05%-32.07M | 155.93%18.25M | -9.48%-37.36M | 13.43%-143.1M | -8.65%-41.84M | 5.00%-34.51M | 33.49%-32.63M | 17.57%-34.13M | -33.20%-165.29M | -199.45%-38.51M |
| Basic earnings per share | 13.33%-0.26 | 151.72%0.15 | -6.67%-0.32 | 38.12%-1.25 | 16.28%-0.36 | 33.33%-0.3 | 53.23%-0.29 | 43.40%-0.3 | -22.42%-2.02 | -184.31%-0.43 |
| Diluted earnings per share | 13.33%-0.26 | 31.03%-0.2 | -6.67%-0.32 | 38.12%-1.25 | 16.28%-0.36 | 33.33%-0.3 | 53.23%-0.29 | 43.40%-0.3 | -22.42%-2.02 | -193.48%-0.43 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data